Article Text

Download PDFPDF
Next generation sequencing pitfalls in diagnosing trypsinogen (PRSS1) mutations in chronic pancreatitis
  1. Frank U Weiss,
  2. Felix Laemmerhirt,
  3. Markus M Lerch
  1. Medicine A, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  1. Correspondence to Professor Markus M Lerch, Medicine A, University Medicine Greifswald, Greifswald 17475, Germany; lerch{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

With interest we read the recent study by Hegyi et al,1 who established that the risk for developing pancreatitis conferred by a haplotype spanning the trypsin locus (PRSS1–PRSS22 3) is strongly dependent on exogenous factors. Changes in PRSS14 or PRSS25 have long been reported to associate with either an increased or a decreased pancreatitis risk, depending on how they contribute to the activation/degradation balance within pancreatic acinar cells. Other germline changes in proteins outside the protease cascade induce pancreatic injury by interfering with intracellular protein processing6 or induction of endoplasmic reticulum stress.7

All recent guidelines agree that mutations affecting the trypsin locus confer the highest risk of developing pancreatitis and put trypsin (PRSS1) in the first line of testing in patients with suspected hereditary pancreatitis (HP).8 Challenges arising from testing these patients include not only the more than 80 known PRSS1 variants of sometimes uncertain clinical relevance (, but also the progression of diagnostic technology towards next generation sequencing (NGS)—especially in conjunction with consumer genetics offered to …

View Full Text


  • Contributors FCW helped in the planning and concept of study. Acquisition of data was done by FUW. Data interpretation, writing of the manuscript and manuscript revision were done by FUW, FL and MML.

  • Funding This work was supported by the PePPP-project (ESF/14-BM-A55_0045/16) the EnErGie/P2 Project (ESF/14-BM-A55-0008/18), and the RESPONSE-project (BMBF grant number 03ZZ0921E).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.